Living meta-analysis and evidence synthesis of therapies for domain #12

 

• COVID 19 hospitalized
• COVID 19 all comers
• COVID-19 mild to moderate
• COVID-19 severe or critically
• COVID 19 outpatients
• COVID-19 (hospitalized or not)
• COVID-19 prophylaxis (children)
• COVID-19 prophylaxis (excluding children)
• infections other than COVID-19
• Long COVID-19
• preventing respiratory virus transmission
• secondary prevention

 

• adjuvant therapies
• anticoagulant
• febuxostat
• anti-inflammatoty and immuno-therapy
• anti-inflammatory therapies
• colchicine
• corticosteroids
• ciclesonide
• Immunostimulants drugs
• convalescent plasma treatment
• Early convalescent plasma.
• interferon
• inhaled interferon
• SNG001 inhaled interferon beta
• peginterferon
• neutralizing antibody
• amubarvimab/romlusevimab (BRII-196 and BRII-198-Brii Biosciences)
• bamlanivimab monotherapy
• bamlanivimab/etesevimab
• Bebtelovimab (LY-CoV1404)
• casirivimab/imdevimab (Ronapreve)
• cilgavimab and tixagevimab (Evusheld)
• regdanvimab (Regkirona- CT-P59-Celltrion)
• sotrovimab (Xevudy; VIR-7831)
• inhaled corticosteroids
• budesonide
• antiandrogenic
• dutasteride
• proxalutamide
• antiviral and associated therapy
• azithromycin
• chloroquine and derivatives
• chloroquine
• hydroxychloroquine
• favipiravir
• fluvoxamine
• hydroxychloroquine plus macrolides
• azithromycin plus hydroxychloroquine
• ivermectin
• ivermectin plus doxycycline
• lopinavir/ritonavir
• molnupiravir
• nirmatrelvir / ritonavir (Paxlovid)
• nitazoxanide
• remdesivir
• sofosbuvir and daclatasvir
• tranexamic acid
• umifenovir (arbidol)
• zinc
• miscellaneous
• camostat mesilate
• povidone-iodine
• Oral antidiabetic drugs
• metformin
• Renin-angiotensin-system-acting agents
• angiotensin receptor blockers (ARBs)
• discontinuation of ACEI/ARB
• Vitamins
• vitamin C
• zinc plus vitamin c
• Vitamin D
• All treatment (not recommended)

    Top evidence (RCT only, high risk of bias excluded) Best available evidence (possibly low or very low) All RCTs All studies (RCT+OBS) see more...